Our Board

Mr Paul Jeans

Chair

Paul Jeans has been chancellor of the University of Newcastle since 2013. Until his retirement in 2000, after a career spanning 42 years, he held senior roles in BHP where he was Executive General Manager/CEO of BHP’s Ferrous Minerals Business and three of its steel businesses, which included responsibility for both Newcastle and Port Kembla steelworks. His earlier career focused on engineering, and he rose to become General Manager of BHP Engineering. Paul has led manufacturing, mining, logistics and technical services businesses through periods of growth, significant change and efficiency improvement, major capital expansion and international operation. He has been chair of the Newcastle Port Corporation, Orinoco Iron CA, Associated Airlines, World Marine and General Insurances and six BHP subsidiary companies. Paul has also been a Director of Foster’s Brewing Group, Energy Australia, Ausgrid and five BHP subsidiary companies.

Mr Richard Vines

Deputy Chair

Founder and CEO of Rare Cancers Australia, Richard Vines attended the University of Melbourne where he studied maths and statistics. He then trained as an actuary but was seduced by the fledgling IT industry before qualifying. After several years working in software development, Richard formed his own software company which he then sold in 1990 before embarking on a second software venture in Europe. In 1996, Richard returned to Australia where he was retained by an American company to establish a sales channel in Australia. In 2001 Richard left the IT industry and worked in a number of not-for-profits associated with retail, politics and health. In 2012, Richard and his wife Kate established Rare Cancers Australia, a patient advocacy group whose mission is to improve the lives and outcomes for patients with rare forms of cancer.

Professor David Thomas

CEO

Professor Thomas is the Chief Executive Officer of the Australian Genomic Cancer Medicine Centre, Head of Cancer Research at Garvan and Director of The Kinghorn Cancer Centre, a collaboration between Garvan and St Vincent’s Hospital, Sydney. David is an oncologist and researcher with a focus on the impact of genomics on cancer medicine and public health. David is the originator of Garvan’s Genomic Cancer Medicine Program, which brought together researchers and clinicians to translate research findings into the clinic, leading to new therapeutic options for patients with advanced disease. He established a national infrastructure for clinical research into sarcomas and has played a significant role in the development of adolescent and young adult oncology. Despite an active clinical role, David has published more than 160 research papers including senior or lead author papers in Molecular Cell, Journal of Cell Biology, Cancer Cell, Journal of Clinical Investigation, Journal of Clinical Oncology, Lancet Oncology, and JAMA Oncology. His H-index is 47.

Emeritus Professor Mark Wainwright AM

Director

Mark Wainwright has more than 25 years’ experience as chair and board member of co-operative ventures in the higher education and industry sectors including numerous co-operative research centres. Prior to accepting the position of Omico Chair, Mark was the Vice-Chancellor and President of the University of New South Wales (UNSW Sydney). He holds a DSc by Research from the University of South Australia, a PhD from McMaster University in Ontario, Canada, as well as a MAppSc in Chemical Engineering and a BAppSci in Applied Chemistry from the University of Adelaide. He is the chair of Intersect Australia Pty Ltd and the Sydney School of Entrepreneurship. He is also a director of AARNet Pty Ltd. He is a member of the International Advisory Board among a long list of distinguished board memberships, external committees, institutes and societies in Australia and overseas.

Professor Chris Goodnow

Director

Garvan Institute for Medical research representative – Executive Director, Garvan Institute of Medical Research, Head of the Immunogenomics Laboratory and the Bill and Patricia Ritchie Foundation, and Chair and Conjoint Professor at UNSW Sydney in the St Vincent’s Clinical School (Faculty of Medicine), Chris is an internationally renowned immunologist. He’s had an extensive international research career and has been a faculty member at Stanford University and the Australian National University, and has been closely involved in several biotechnology start-up companies. He joined Garvan in 2015 and is best known for integrating molecular genetics and genomics with immunology, for which he has received numerous awards as well as election to the Australian Academy of Science, the UK Royal Society and the US National Academy of Science.

Mr Bruce Goodwin

Director

Medicines Australia representative – Managing Director, Janssen Australia and New Zealand, Bruce Goodwin’s career with the Johnson & Johnson family of companies spans 35 years. He has been in general management roles for the last ten years including two terms in his current role of Managing Director Janssen Australia and New Zealand, and three years as President and Representative Director of Janssen Japan. Prior to general management, he’s held management board director positions in sales, marketing and in finance, as well as having gained valuable experience in global licensing and acquisitions. His service with Johnson & Johnson outside of his home country, Australia, includes postings to Janssen Japan, Janssen Belgium and Janssen United Kingdom. Bruce is a respected industry leader and is currently an elected director and board member of Medicines Australia, a role he has also held previously. While in Japan, he served as vice-chair of the Japan bBased Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA). Bruce has a strong track record in advocating for policies that support timely and affordable access to innovative medicines and in 2017, he was a key member of the Cancer Drugs Access Committee. Bruce holds an economics degree from Macquarie University and an MBA from Macquarie Graduate School of Management, and is a graduate member of the Australian Institute of Company Directors (GAICD).

Professor John Simes

Director

University of Sydney representative – Director, NHMRC Clinical Trials Centre, University of Sydney. Professor Simes, who is also director of the Sydney Catalyst Translational Research Centre, is a leading international researcher in clinical trials, particularly in cancer, cardiovascular disease, diabetes and neonatal medicine. In his position of Senior Principal Research Fellow and Director of the NHMRC CTC, University of Sydney, he leads a team of 200 who collaborate nationally and internationally to improve health practice and outcomes through better use of clinical trials research. His work has had a significant impact on current knowledge and clinical practice. He practices as a medical oncologist in neuro-oncology.

Professor Kathryn North

Director

Australian Genomics Health Alliance representative – Professor North is a director of the Murdoch Children’s Research Institute and the David Danks Professor of Child Health Research at the University of Melbourne. She is a national and international leader in genomic medicine. Kathy is co-chair of the Global Alliance for Genomics and Health – a collaborative network of more than 500 organisations from more than 45 countries – and leads the Australian Genomics Health Alliance, a national network of more than 80 institutions whose mission is to provide evidence and practical strategies for the implementation of genomic medicine in the health system. She is a Foundation Fellow of the Australian Academy of Health and Medical Science; chairs the International Advisory Board of the Great Ormond Street Institute of Child Health (UK) and is a member of the board of the Victorian Comprehensive Cancer Centre. In 2019 Kathy was awarded a Companion (AC) of the Order of Australia in recognition of her eminent service to genomic medicine nationally and internationally, to medical research in the fields of genetics, neurology and child health, and as a mentor and role model.

Professor Michael P. Brown

Director

Member representative – Central Adelaide Local Health Network, South Australia – Professor Brown is a director of the Cancer Clinical Trials Unit at Royal Adelaide Hospital. He heads its melanoma research program and chairs its fortnightly melanoma multidisciplinary meeting. He is a senior consultant medical oncologist in the Royal Adelaide Hospital Cancer Centre. Professor Brown sub-specialises in the care of patients with advanced melanoma or lung cancer. His clinical research is focused mainly on facilitating rapid access to new targeted therapies and on early-phase clinical trials testing new immunotherapies for the treatment of melanoma and lung cancer. His laboratory research is focused mainly on understanding better how to direct T cells toward cancer targets. Professor Brown has published 119 papers, including 17 in high impact journals (Lancet, Lancet Oncology, Nature Medicine, Cell, Blood, Clin Cancer Res, Oncogene, Ann Oncology, J Nucl Med) and has an H-index of 30.

Professor Ricky Johnstone

Director

Member representative – Professor Johnstone is a cancer researcher who has utilised genetic mouse models of haemopoietic malignancies and solid tumours to understand the epigenetic changes that underpin tumour onset and progression, and to develop new therapies that target epigenetic and transcriptional regulatory proteins. Professor Johnstone has recently discovered how epigenetic-based agents can engage the host immune system to drive prolonged therapeutic responses. Professor Johnstone and his team are advancing these fundamental discoveries through the implementation of clinical trials that combine epigenetic and immunotherapeutic agents. Professor Johnstone has published a total of 227 papers with >25,000 total citations, and he has an H-index of 74.

Tze Masters

Director

Tze is a high impact business leader with strong strategic skills, financial and investment capabilities. Tze has over twenty years experience in the investment, finance and banking sectors, coupled with a high level of general management, entrepreneurial and communication skills.

A/Professor Paul Martin

Company Secretary

Paul is an associate professor at the University of Sydney and lectures in banking and risk management. He is also currently the company secretary of both Intersect Australia Limited and the Sydney School of Entrepreneurship Limited. Paul has over twenty years’ experience in the banking industry, having worked for a number of banking organisations including Advance Bank of Australia, the Australian Financial Markets Association, Hong Kong Bank of Australia Limited (HSBC), Australian Bank Limited and the Commonwealth Banking Corporation. He was previously the chief financial officer and company secretary of the Securities Industry Research Centre of Asia-Pacific (SIRCA), and was responsible for all aspects of the company’s management and operating functions including liaison with SIRCA’s key industry partners the ASX, the Sydney Futures Exchange, the Australian Financial Markets Association and Thomson Reuters.

Interested in knowing more?

Get in touch